PrEP approved for adolescents in US

Sybil Hosek presenting at AIDS 2016. Photo by Liz Highleyman, hivandhepatitis.com
Liz Highleyman
Published: 21 May 2018

The US Food and Drug Administration (FDA) last week approved Truvada pre-exposure prophylaxis (PrEP) for adolescents, which will likely make the HIV prevention pill more widely available to a group with a disproportionately high risk of infection.

Doctors in the US can prescribe approved drugs as they deem appropriate, and many clinics have already been providing PrEP off-label for teens. But the approval should make it available in more places and make it easier to obtain insurance coverage.

"The approval of oral PrEP for adolescents is a milestone in HIV prevention for youth," said Sybil Hosek of Stroger Hospital in Chicago, who conducted studies of PrEP for teens and young adults. "This indication allows prescribers to feel confident in the safety and tolerability of PrEP for sexually active youth."

Young people age 13 to 24 accounted for 21% of new HIV diagnoses in 2016, according to the US Centers for Disease Control and Prevention. Over 80% of these cases were among young gay and bisexual men, with young black and Latino men being most heavily affected.

In July 2012, the FDA approved Gilead Sciences' Truvada (tenofovir DF/emtricitabine) as PrEP for people age 18 and older. Truvada has long been approved for HIV treatment for both adults and paediatric patients, but until now the prevention indication did not include adolescents. The new approval covers youth weighing more than 35kg, about the average weight of an 11 year old.

Clinical trials in adults have shown that, when taken consistently, Truvada reduces the risk of HIV infection for men who have sex with men by around 90%, with infection rates approaching zero for people who take it at least four times per week.

Studies shown that young adults and adolescents can also do well on PrEP, but they may need more frequent monitoring and support. Study ATN 113 enrolled young gay and bisexual men age 15 to 17 in six US cities. A previous companion study, ATN 110, enrolled young men age 18 to 22.

ATN 113 included 79 participants, with a mean age of 16.5 years. Nearly a third were black, a similar proportion identified as mixed or other race/ethnicity, 21% were Hispanic/Latino, 14% were white and 3% were Asian. They reported having an average of two sex partners during the past month, 60% reported condomless receptive anal sex with their last partner, 17% said they had ever been paid for sex and 15% had tested positive for sexually transmitted infections.

Participants received once-daily Truvada along with risk reduction counselling and adherence support. The first three follow-up visits were a month apart, but then were extended to every three months. To assess adherence, tenofovir levels were measured in dried blood spots.

As Hosek reported at the 2016 International AIDS Conference in Durban, South Africa, three study participants became HIV positive during the study. The incidence rate of 6.41 per 100 person-years was among the highest ever seen in a PrEP programme, and was twice the rate seen in ATN 110.

Adherence was initially good, with a majority of participants achieving protective tenofovir levels during monthly visits. But it dropped off after they switched from once-monthly monitoring to every thee months.

Side-effects were mostly minor and similar to those observed in adults taking Truvada. Although it is generally safe and well tolerated, tenofovir DF can sometimes cause kidney toxicity and bone loss. Kidney problems are less likely to occur in young people, but bone loss could be a larger concern, especially in those who are still growing.

An analysis from ATN 110 showed that young adults experienced modest but significant bone loss after starting Truvada, but that this stabilised after a year and began to recover after stopping the drug. While these findings are reassuring, results from an analysis of bone loss among the adolescents in ATN 113 have not yet been reported.

People seeking PrEP first need to get an HIV test to ensure they are not already infected, as well as hepatitis B and kidney function tests, as Truvada should not be used by people with pre-existing kidney problems. HIV testing should then be repeated at least every three months while taking PrEP, along with regular tests for sexually transmitted infections.

"It is critical that we as providers do all we can to simplify access to HIV prevention for adolescents and young adults," Hosek told aidsmap.com.

"Young people may need more time, and we need to give it to them," she said when she presented the ATN 113 results two years ago. "If they want PrEP, we need to help them make it work."

Tell us why you visited aidsmap today
minimise

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?

close

Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.